These new findings may lead to a promising therapeutic strategy for severe rickettsioses by targeting NLRP3 to ameliorate endothelial permeability/inflammation/injury as an adjunctive approach to accompany anti-rickettsial treatment. Here, NLRP3 is linked to Rickettsiosis.